News

April 8, 2015 – Caisson Biotech Wins Innovation Recognition Award

March 11, 2014 – Caisson Biotech Expands HEPtune™ Drug Delivery Deal with Novo Nordisk

May 1, 2013 – Emergent Technologies and Caisson Biotech Form Strategic Alliance with Local Health Care Providers to Improve Delivery and Performance of a Therapeutic Drug

May 1, 2012 – Caisson Biotech Enters Into Development and License Agreement with Novo Nordisk

Glycobiology: August 2017
Synthesis and Characterization of Heparosan-Granulocyte-Colony Stimulating Factor Conjugates: a natural sugar-based drug delivery system to treat neutropenia

Glycobiology: August 2017
Heparosan-Coated Liposomes for Drug Delivery

Poster Presented by Novo Nordisk A/S: July 2016
Increasing the in vivo half-life of factor VIIa by attachment of the natural polysaccharide heparosan 
Courtesy of Novo Nordisk A/S

Poster Presented by Novo Nordisk A/S: June 2015
Heparosan glycol-conjugates of rFVIII and rFIX show prolonged circulating half-life in haemophilia mouse models
Courtesy of Novo Nordisk A/S

Drug Development and Delivery: January 2013
Heparosan-Based Conjugates – Heptune: A Process of Conjugating a Naturally Occurring Sugar Molecule, Heparosan, to a Drug for Enhanced Drug Delivery

Drug Development and Delivery: July/August 2012
Caisson Biotech: Innovation in Drug Delivery Using a Naturally Occurring Sugar Molecule

The Oklahoman: June 22, 2012
Drug Delivery System Agreement Opens Doors for Caisson Biotech

Drug Delivery News: June 2012
Hustling on Half-lives